ライフサイエンスコーパス: length of stay

1 ter outcomes except for a marginally shorter length of stay.

2 with changes in mortality, readmissions, or length of stay.

3 ospital mortality and death or prolonged ICU length of stay.

4 complication, reoperation, readmission, and length of stay.

5 e observed, without subsequent difference in length of stay.

6 n serum IL-6, IL-10, C-reactive protein, and length of stay.

7 rates based on insurance type, and hospital length of stay.

8 ssociated with improved outcomes and shorter length of stay.

9 with increased mortality and longer hospital length of stay.

10 vir may have little to no effect on hospital length of stay.

11 ac interventions, hospitalization costs, and length of stay.

12 d a 0.5 day (95% CI, 0.2 to 0.7 day) shorter length of stay.

13 ferral to hospice as well as shorter hospice length of stay.

14 I for in-hospital complications and hospital length of stay.

15 The primary outcome was length of stay.

16 AKI (stage 2 or 3), inpatient mortality, and length of stay.

17 Secondary outcomes included length of stay.

18 hin the first 48 hours, and ICU and hospital length of stay.

19 ctions, non-delivery-related admissions, and length of stay.

20 ciated with lower mortality rate and shorter length of stay.

21 y health outcomes were in-hospital death and length of stay.

22 dium difficile infection rates, and hospital length of stay.

23 intensive care units regardless of patients' length of stay.

24 urvival continued to decline with increasing length of stay.

25 P was associated with a reduction of the ICU length of stay.

26 ct mortality, need for ICU admission, or ICU length of stay.

27 erity of illness, need for vasopressors, and length of stay.

28 phrotoxicity, any reported AE, mortality and length of stay.

29 xpensive and might decrease overall hospital length of stay.

30 rt, intensive care unit (ICU) admission, and length of stay.

31 The a priori chosen primary outcome was ICU length of stay.

32 complications had prolonged ICU and hospital length of stays.

33 , and patients who were admitted had shorter lengths of stay.

34 es difficile infection, and ICU and hospital lengths of stay.

35 verity-adjusted mortality, readmissions, and lengths of stay.

36 everity adjusted mortality, readmissions, or lengths of stay.

37 A cohort of inpatient operations (length of stay 1 day or greater) was obtained from a con

38 s (n=282), major complications (n=1539), and length of stay (101 183 days) over the 4-year study peri

39 -associated major bleeding had longer median length of stay (11 vs 6 d; p = 0.02), and higher total c

40 2 days vs 1 day) and shorter median hospital length of stay (12 vs 11 days) (all P < 0.05).

41 ile range) post mechanical ventilation onset length of stay (13 [8-20] vs 4 d [1-8 d]) and hospital c

42 , reinfection (38.0% vs 56.7%; P < .01), and length of stay (14.5 +/- 14.9 vs 22.6 +/- 19.0 days; P <

43 es (2.8 +/- 2.1 vs 4.1 +/- 2.5; P < .01) and length of stay (18.6 +/- 17.5 vs 28.2 +/- 17.7; P < .01)

44 vs 2.9%), shorter median intensive care unit length of stay (2 days vs 1 day) and shorter median hosp

45 greatest reduction in mortality (5.71%) and length of stay (2.45 d).

46 ts working 7+ consecutive days (adjusted ICU length of stay = 2.85 d), care by an intensivist working

47 < 0.001) and had longer hospital durations (length of stay 29 vs 17 d; p < 0.001).

48 econds, estimated blood loss 50 (32) mL, and length of stay 3 (1) days.

49 ecutive days was associated with shorter ICU length of stay (3 consecutive days: 0.46 d fewer, p = 0.

50 e, SSIPK+ patients had shorter mean hospital length of stay (3.1 vs 5.4 d, P < 0.01) and had fewer un

51 entilation, intensive care unit and hospital length of stay, 3-month and 1-year survival, continuing

52 35.3% vs 52.3%), CR-POPF (0.9% vs 7.9%), and length of stay (6 vs 8 days).

53 Length of stay (6.5 versus 3.2 days, P < 0.01), readmiss

54 F, those with previous HF experienced longer length of stay (8 days vs. 6 days; p < 0.001), increased

55 ity but did result in reductions in hospital length of stay, accompanied by improvements in in qualit

56 An increasing length of stay (adjusted odds ratio [aOR] per day, 1.03;

57 year, which declined over time, and a longer length of stay (adjusted relative ratio [aRR] = 1.13, 95

58 Reducing length of stay after kidney transplant has an unknown ef

59 E (60.8% vs. 64.9%, p 0.177), with a reduced length of stay after transthoracic MIE (median 12 vs. 15

60 acteristic was adjusted for ICU and hospital length of stay along with mobility status prior to hospi

61 The median length of stay among patients with acute coronary syndro

62 the cumulative burden of revisit-associated length of stay and cost from all procedures was calculat

63 ich was significantly associated with longer length of stay and cost.

64 arin-associated major bleeding had increased length of stay and costs.

65 cquired infections with regard to attributed length of stay and costs.

66 ted with ICU readmission, increased hospital length of stay and death and are not predicted by ICU or

67 Premorbid low admissions had longer adjusted length of stay and higher adjusted mortality than premor

68 on; secondary outcomes included ICU/hospital length of stay and ICU/hospital mortality.

69 ease health care costs, because of increased length of stay and increased frequency of readmissions d

70 SPPB impairment is associated with longer length of stay and increased mortality in kidney transpl

71 After adjusting length of stay and mortality for covariates, undocumente

72 Other collected variables included length of stay and primary diagnosis on admission.

73 Secondary outcomes such as inpatient length of stay and readmissions were also assessed.

74 Secondary endpoints were the ICU length of stay and the 28-day all-cause mortality.

75 The median length of stay and total hospitalization costs were 14 d

76 These women had longer lengths of stay and higher total charges than women with

77 Metastatic complications, length of stay, and 30-day mortality were progressively

78 -effectiveness, coverage, defaulting, death, length of stay, and average daily weight and MUAC gains.

79 Thirty-day nonelective readmission rates, length of stay, and causes of readmission were compared.

80 oring (arterial/central catheters), hospital length of stay, and cost.

81 s in the duration of mechanical ventilation, length of stay, and cost.

82 year mortality, quality-adjusted life-years, length of stay, and costs of care.

83 Thirty-day readmission, mortality, length of stay, and costs were assessed using Cox propor

84 ce on inpatient mortality, discharge status, length of stay, and costs.

85 and long-term mortality, clinical outcomes, length of stay, and discharge disposition to home.

86 circulatory support, hospitalization costs, length of stay, and discharge disposition.

87 Outcomes were mortality, hospital length of stay, and discharge disposition.

88 were more likely to be younger, have shorter length of stay, and experience similar mortality rates t

89 with increased hospital mortality, prolonged length of stay, and higher costs among survivors.

90 e was associated with longer median hospital length of stay, and higher mean costs.

91 hanical ventilation, longer ICU and hospital length of stay, and higher mortality.

92 ng transfusion, acute kidney injury, stroke, length of stay, and hospital costs).

93 eeding, transfusion, vascular complications, length of stay, and hospital costs.

94 case mix, admission volume, home health use, length of stay, and hospital use within 90 days of SNF a

95 intensive care unit length of stay, hospital length of stay, and in-hospital mortality.

96 omplications, reinterventions, reoperations, length of stay, and mortality.

97 urgical morbidity, length of ICU stay, total length of stay, and pathology reports were reviewed.

98 as the potential to reduce antibiotic usage, length of stay, and patient charges.

99 in total inpatient opioid use, pain scores, length of stay, and patient-reported quality of life.

100 yed gastric emptying, percutaneous drainage, length of stay, and readmission.

101 on, and measured complications and severity, length of stay, and readmissions.

102 fter intubation, PaCO2 after intubation, ICU length of stay, and short-term mortality.

103 Healthcare use included episodes of care, length of stay, and total charges/payments.

104 d postoperative noninfectious complications, length of stay, and up to 30-day mortality.

105 hospital length of stay, intensive care unit length of stay, and ventilator days) did not differ betw

106 (12.8 d [7.0-23.6 d] vs 10.8 d [5.9-20.3 d]) length of stay, and were more likely to die in the ICU (

107 es positive had higher case-fatality, longer lengths of stay, and higher costs than patients who had

108 similar perioperative mortality, but longer lengths of stay, and higher rates of postoperative renal

109 after SBT; intensive care unit and hospital lengths of stay; and hospital and 90-day mortality.

110 ss OR 1.71, 95%CI 1.66-1.77] and an extended length of stay (anxiety/depression OR 1.45, 95% CI 1.44-

111 evidence that patients with increases in ICU length of stay beyond 48 hours have significantly increa

112 ted more than half of the revisit-associated length of stay burden from all procedures, with the high

113 ersus 1.6%, IDR 3.1 [95% CrI 2.5-3.7]), mean length of stay by 1.8-fold (19.2 versus 10.5 days, IDR 1

114 Use of the assessment reduced the mean length of stay by 20 days and total direct cost by 33%,

115 ntibiotic completion) and shortened hospital length of stay by 23.5 days.

116 estimated risk of mortality, graft loss, and length of stay by recurrent falls before KT using adjust

117 , duration of mechanical ventilation, or ICU length of stay by timing of intubation.

118 nd cheap and might decrease overall hospital length of stay.Clinical Trials Registration: NCT03966534

119 0.31), acute kidney injury, ICU or hospital length of stay compared with control.

120 tric Risk of Mortality III-adjusted expected length of stay compared with noncases.

121 ompromised patients have shorter median PICU length of stay compared with patients without immunocomp

122 HCR reduces bleeding, ventilator time, and length of stay compared with traditional CABG.

123 $167 669+/-$208 577; P<0.001) but comparable lengths of stay compared with men.

124 , with no significant difference in hospital length of stay, complications, or transfusion requiremen

125 he impact on ED dwell time, ICU and hospital lengths of stay, complications, and in-hospital mortalit

126 each week increase in gestation, the average length of stay decreased by 4% (95% CI, 2-6%).

127 By contrast, mean length of stay decreased by around 2% annually for strok

128 Mortality and length of stay decreased in the post-Affordable Care Act

129 Similarly, although ICU and hospital lengths of stay decreased by 0.08 (95% CI, -0.08 to -0.0

130 al allograft survival and decreased hospital length of stay despite longer kidney cold ischemia.

131 ICU mortality and length of stay did not change postimplementation.

132 r time in admissions and outcomes, including length of stay, discharge destinations, and mortality of

133 cluding patient demographic characteristics, length of stay, disposition, and charges.

134 y outcomes were ICU length of stay, hospital length of stay, duration of mechanical ventilation, use

135 ival to hospital discharge, ICU and hospital lengths of stay, duration of invasive mechanical ventila

136 ED length of stay (ED-LOS); ICU length of stay (ICU-LOS); h

137 ient selection, discharge to postacute care, length of stay, emergency department use, readmissions,

138 drainage, and reoperation while achieving a length of stay equal to or less than the 75th percentile

139 The mean length of stay for readmitted patients was significantly

140 rates, 28-day case fatality rates, and mean length of stay for stroke, ischaemic heart disease, and

141 ds ratio, 1.3; 95% CI, 1.0-1.6) and a longer length of stay for the kidney transplant surgery (mean d

142 secondary composite outcome of death or ICU length of stay greater than 48 hours, the risk model con

143 age > 64 years, non-alcoholic cirrhosis, and length of stay > 10 days were significant predictor of c

144 infections, hemodialysis, liver biopsy, and length of stay > 10 days were the predictors of 30-day r

145 spitals had a higher percentage of prolonged length of stay >14 days (9.3% versus 2.4%, P=0.006), pro

146 operative findings of complicated disease or length of stay>=6 d).

147 ubation, duration of mechanical ventilation, length of stay, health-related quality of life, and mort

148 LOS); ICU length of stay (ICU-LOS); hospital length of stay (HLOS); complications; and in-hospital mo

149 apid response team call, intensive care unit length of stay, hospital length of stay, and in-hospital

150 Secondary outcomes were ICU length of stay, hospital length of stay, duration of mec

151 ED length of stay (ED-LOS); ICU length of stay (ICU-LOS); hospital length of stay (HLOS)

152 Secondary outcomes included hospital length of stay, ICU readmissions, and mortality (ICU and

153 Secondary outcomes included ICU and hospital lengths of stay; ICU, hospital, and 28- and 90-day morta

154 4 vs 12.2 years, P = 0.5), and postoperative length of stay in a hospital (27.2 vs 25.6 hours, P = 0.

155 morbidity-mortality composite end point, and length of stay in an inverse linear fashion.

156 ehicle-traumatic AKI-RRT patients had longer length of stay in hospital [median (IQR):15 (5-34) days

157 r gestation was also associated with reduced length of stay in hospital: each week increase in gestat

158 difference, -1.7 d [-2.5 to -0.8 d], n = 32, length of stay in ICU (-1.2 d [-2.5 to 0.0 d], n = 32) b

159 re, artesunate was associated with a shorter length of stay in the ICU, which supports the actual the

160 wn to reduce the time on ventilation and the length of stay in the intensive care unit (ICU).

161 does not appear to decrease with increasing length of stay in unselected patients admitted to ICUs i

162 s not associated with significant changes in length of stay (incidence rate ratio, 1.02; 95% confiden

163 uded an evaluation of in-hospital mortality, length of stay, infusion-related reactions, and thrombot

164 er to inpatient care, and hospital outcomes (length of stay, intensive care unit [ICU] admission, mec

165 nical variables (in-hospital death, hospital length of stay, intensive care unit length of stay, and

166 similar for CAS and CEA although readmission length of stay is longer after the latter.

167 hrombocytopenia is associated with increased length of stay, longer duration of organ support, major

168 Although length of stay (LoS) after childbirth has been diminishi

169 Run charts evaluated index length of stay (LOS) and 90-day comprehensive complicati

170 predict adverse clinical outcomes [increased length of stay (LOS) and complications] in complex pedia

171 enation (ECMO), and on index hospitalization length of stay (LOS) and early posttransplant complicati

172 s to discharge, which could prolong hospital length of stay (LOS) and increase financial burden.

173 has been shown to be associated to hospital length of stay (LOS) and mortality.

174 f preoperative anticholinergic exposure with length of stay (LOS) and other outcomes in older people

175 Studies estimating excess length of stay (LOS) attributable to nosocomial infectio

176 -time notification (RTN) have shown improved length of stay (LOS) in bacteremia.

177 horter duration of intensive care unit (ICU) length of stay (LOS) prior to cannulation (5.6 days vs.

178 urgery in hospitals experiencing significant length of stay (LOS) reductions over time are exposed to

179 unction (DGF) using logistic regression, and length of stay (LOS) using negative binomial regression.

180 The length of stay (LoS) was not different (p = 0.73) betwee

181 d time to oral antibiotic stepdown, hospital length of stay (LOS), all-cause 30-day mortality, 7-day

182 ncluded ERP compliance rates, complications, length of stay (LOS), and 30-day readmission rates were

183 rimary endpoints were in-hospital mortality, length of stay (LOS), and cost.

184 new disability (primary); safety incidents, length of stay (LOS), and institutional discharge (secon

185 (NIV), invasive ventilation (IMV), hospital length of stay (LOS), and parental morphine equivalents

186 Mortality, length of stay (LOS), and probability of discharge home

187 icrobial consumption, in-hospital mortality, length of stay (LOS), and the incidence of Clostridioide

188 PD severity and clinical outcomes, including length of stay (LOS), duration of respiratory support, r

189 y outcomes included initial and total 30-day length of stay (LOS), emergency department (ED) visits,

190 ms of muscle and adipose tissue and hospital length of stay (LOS), number of any postoperative compli

191 Primary outcome was length of stay (LOS), other variables included functiona

192 nt difference in clinical severity, hospital length of stay (LOS), rate of functional independence (2

193 s 90-day mortality; secondary endpoints were length of stay (LOS), re-operation, and re-admission to

194 es' contribution to patient flow in terms of length of stay (LOS), triage time, and other associated

195 ribe the relationship between CIT on DGF and length of stay (LOS).

196 ply costs, procedure time, and postoperative length of stay (LOS).

197 anned readmissions, mortality, postoperative length of stay (LOS)] were compared between propensity s

198 ment and isolation strategies and reduce the length-of-stay (LOS).

199 Primary outcomes included lengths of stay (LOS), antibiotic usage, and relapse inc

200 was associated with higher body mass, longer length of stay, lower Braden score, pressure injury prev

201 anaged with early ID involvement had shorter length of stay, lower spending, and lower mortality in t

202 e-interventions; no unplanned ICU admission; length of stay <=21 days; no 30-day readmission; and no

203 Previous reports suggest increasing length of stay may be associated with poor outcomes.

204 5% CI -0.54 to -0.31, P < 0.00001), hospital length of stay (mean difference -0.45, 95% CI -0.65 to -

205 % CI, 0.57-1.52; moderate certainty), or ICU length of stay (mean difference, 0.05 d fewer; 95% CI, 0

206 0.34-1.22; moderate certainty) and hospital length of stay (mean difference, 0.98 d fewer; 95% CI, 2

207 length of stay (median 5 vs 5.5 d), hospital length of stay (median 10 vs 11 d), in-hospital mortalit

208 dmission rates (61% vs 44%), longer hospital length of stay (median 19 vs 8 d), and higher in-hospita

209 We found no difference in ICU length of stay (median 4 d [interquartile range, 3-5 d]

210 s with ICH were more likely to have a longer length of stay (median 5 days vs 4 days, p < 0.001) and

211 There was no significant difference in ICU length of stay (median 5 vs 5.5 d), hospital length of s

212 High-flow nasal cannula may reduce ICU length of stay (moderate certainty) and hospital length

213 th of stay (moderate certainty) and hospital length of stay (moderate certainty) compared with noninv

214 dvanced practice provider care, including on length of stay, mortality, and quality-related metrics,

215 Clinical characteristics and outcomes (length of stay, need for intensive care unit, mechanical

216 re was no significant difference in hospital length of stay, need for intubation, length of intubatio

217 Secondary outcomes included lengths of stay, need for RRT, and mortality.

218 edullin was also associated with a prolonged length of stay (odds ratio, 1.85; 1.49-2.29) and, after

219 VOU or VACU or both settings, with a median length of stay of 11 days.

220 verage, 7 more days in hospital (for a total length of stay of 14 days) (PTD = 0.53).

221 Over a median hospital length of stay of 7 days (interquartile range, 3 to 14 d

222 hospital-requiring procedures, had a median length of stay of only 3 days, but still incurred both s

223 were similar between groups except hospital length of stay (opioid users 35 versus nonusers 27 d, P

224 rioperative music on medication requirement, length of stay or costs in adult surgical patients were

225 rovided: incidence, prevalence, attributable length of stay or healthcare cost due to hospital-acquir

226 with physician resident/fellows measured as length of stay or mortality.

227 ormance to experienced surgeons in prolonged length of stay [OR 1.08; 95% CI (1.02-1.15), P = 0.015],

228 admission [OR, 0.82 (95% CI, 0.57-1.2)], and length of stay [OR, 0.99 (95% CI, 0.86-1.1)] compared to

229 also no effect on postintubation PaCO2, ICU length of stay, or 28-day mortality.

230 with changes in patient selection, payments, length of stay, or clinical outcomes.

231 complications, apneic time, oxygenation, ICU length of stay, or overall survival when used in the per

232 resources was not associated with mortality, length of stay, or treatment intensity (mechanical venti

233 ariates, undocumented immigrants had shorter length of stay (p < 0.05) and there was no difference in

234 renteral nutrition, and an extended hospital length of stay (P < 0.05).

235 and kidney survival (P = 0.02) and decreased length of stay (P = 0.001), kidney allograft failure (P

236 02), mortality (P < 0.05), and postoperative length of stay (P = 0.002) decreased.

237 t and kidney survival (p=0.02) and decreased length of stay (p=0.001), kidney allograft failure (p=0.

238 4), seroma (RR 0.43, 95% CI: 0.32-0.59), and length of stay (pooled mean difference -2.01, 95% CI: -2

239 No significant reduction in length of stay (pooled SMD -0.18 [95% CI -0.43 to 0.067]

240 The mean (SD) length of stay pre Affordable Care Act was 13.92 (17.42)

241 ious complications and a tendency to shorten length of stay, preoperative IMN should be encouraged in

242 unt have comparable mortality but discrepant length of stay, procedural complication rates and reinte

243 tive or non-urgent for 362 (90%), and median length of stay [Q1, Q3] was 5.1 days [1.9, 9.9].

244 f which differed significantly by age group (length of stay range from 17 d [18-49 yr] to 9 d [80-90

245 The attributable length of stay ranged from 0.9 to 14.1 days and the attr

246 issions, avoidable admissions, and prolonged length of stay; receipt of cancer screening; Agency for

247 erative atrial fibrillation, ICU or hospital length of stay remain unclear.

248 s not associated with longer ICU or hospital length of stays, requirement for renal replacement thera

249 nd RR 1.63, 95% CI 1.18-2.26, respectively], length of stay (RR 1.35, 95% CI 0.77-1.92 and RR 0.98, 9

250 intraoperative heated chemo, female sex, and length of stay shorter than 14 days.

251 Secondary outcomes included postoperative length of stay, surgical site infection, sepsis, pneumon

252 probiotics also led to a reduction in total length of stay (synbiotics weighted mean difference: -3.

253 obotic pancreatectomy patients had a shorter length of stay than patients who underwent open pancreat

254 ft Pediatric had higher ratios of actual ICU length of stay to Pediatric Risk of Mortality III-adjust

255 blood pressure with vasopressor duration and length of stay using multivariable competing risk models

256 ual patient risk for mortality and prolonged length of stay using the Pediatric Heart Network Single

257 e trials, the outcomes of interests were ICU length of stay, vasopressor-free days, ventilation-free

258 rce utilization, including longer cumulative length of stay (VH: Rate ratio [RR] 3.15[95% CI 2.86-3.4

259 The median ICU length of stay was 1.57 days (interquartile range, 0.82-

260 ICU length of stay was 13 days (7-21 d) and mortality at 28

261 The median length of stay was 3 days (interquartile range, 1-5), 14

262 [IQR] 46 to 73 years), median postoperative length of stay was 3 days (IQR 1 to 6), and inpatient 30

263 g MRSA patients in the United States, median length of stay was 4 days shorter and 30-day hospital re

264 Median hospital length of stay was 6.0 days (3.0-13.0 d).

265 The mean length of stay was 6.9 days (+/- 5.6 d) with the mean Se

266 The median postoperative length of hospital length of stay was 8 days, with the majority of patients

267 Median hospital length of stay was almost 1 day longer at each of the di

268 Length of stay was also no different at a median of 7 da

269 Significant reduction in median hospital length of stay was also observed in the early corticoste

270 Median length of stay was increased after birth in ASD (+ 6.5 h

271 ative time, blood loss, ICU stay and overall length of stay was just over 2 h, 28 mL, 1.6 days and 3.

272 ; 8.4% versus 7.9%, P=0.20), and readmission length of stay was longer for CEA than CAS (2 versus 1 d

273 Median postoperative length of stay was longer for patients with type 4 than

274 Hospital length of stay was longer in patients with medical compl

275 As compared to the baseline period, the ICU length of stay was reduced by 3.2 days in the interventi

276 Length of stay was reported as median and interquartile

277 or urgent and emergency cases, and a reduced length of stay was seen for such patients.

278 The target length of stay was set at eighth postoperative day (POD)

279 standard arm: 32.3%, P<0.001) and median ED length of stay was shorter (0/1-hour arm: 4.6 [interquar

280 Length of stay was shorter (4.8 days [25th to 75th perce

281 vs diversion: 182/311 [58.5%]; P = .03), and length of stay was shorter (control: 30 hours [interquar

282 sus diversion: 182/311 - 58.5%, p=0.03), and length of stay was shorter (control: 30 hours, interquar

283 Median length of stay was shorter and hospital costs higher wit

284 The surgery-related length of stay was significantly longer in patients with

285 Median length of stay was significantly lower in LB group (2.0

286 ged critical illness cutoff (90th percentile length of stay) was greater than or equal to 35 and grea

287 ent outcomes, such as hospital mortality and length of stay, was analyzed.

288 atistics results for prediction of prolonged length of stay were 85 +/- 3% accuracy and AUROC 0.94 +/

289 CONUT and length of stay were both predictive for the number of co

290 ds to complications and prolonged (>=6 days) length of stay were built.

291 Mortality and length of stay were comparable and consistent with histo

292 lity, major complications, and postoperative length of stay were evaluated using Bayesian models.

293 Hospital and ICU length of stay were reduced by 23.6% and 38%, respective

294 the median intensive care unit and hospital lengths of stay were 2.0 and 6.0 days, respectively.

295 des difficile infection and ICU and hospital lengths of stay were not significantly different by trea

296 re quality, time available for teaching, and length of stay when the patient to intensivist ratio is

297 ere identified as risk factors for prolonged length of stay whereas robotic surgery (OR 0.62; P = 0.0

298 inpatient readmission) and their associated lengths of stay within 30 days of discharge.

299 sociated with trends toward shorter hospital length of stay without increases in ICU readmissions or

300 secutive days is associated with reduced ICU length of stay without negatively impacting mortality.